Granules India Limited Share Price & Analysis

Granules India secures first-to-file ANDA for Sodium Oxybate

*Granules India secures first-to-file ANDA for Sodium Oxybate Extended-Release for Oral Suspension.* This milestone could lead to 180-day marketing exclusivity upon FDA approval. The drug has a US market size of **$400 million** annually. Approval may boost revenues significantly in the coming years. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma

Granules India to hold shareholders meeting on August 06, 2026.

*Granules India to hold shareholders meeting on August 06, 2026.* The event is a routine corporate disclosure with no immediate financial implications. Shareholders may discuss strategic matters, but no major announcements are expected. It does not impact near-term trading sentiment. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting

Granules India to host analyst and investor meet

*Granules India to host an analyst and institutional investor meet.* The event is part of its ongoing investor outreach. Details on strategic updates may emerge. No financial announcements confirmed yet. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

Analyst recommends Granules India, Genus Power for buys today

*Analyst Kush Bohra recommends buying Granules India and Genus Power with target prices.* The call highlights potential upside based on current valuations and sector momentum. **Target prices** were specified but not disclosed in the headline. Investors may consider these for short- to medium-term gains. 📊 *STOCKS:* GRANULES, GENUSPOWER | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #BrokerCall

Granules India to host analyst and investor meet

Granules India announced an upcoming analyst and institutional investor meet. The event aims to provide updates on company strategy and operations. *No major financial announcements or guidance changes were disclosed.* 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet

Granules receives 4 USFDA observations for US facility

*Granules receives 4 USFDA observations for US facility.* The USFDA raised four Form-483 observations following an inspection of Granules’ manufacturing plant in the US. These observations highlight compliance issues that may impact drug approvals and exports. Granules must respond with corrective actions to avoid regulatory escalation. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Granules receives USFDA EIR for Chantilly plant

*Granules receives USFDA EIR for Chantilly plant* — Granules India has received an Establishment Inspection Report (EIR) from the USFDA for its Chantilly, Virginia facility following a routine inspection. The EIR indicates no critical observations, a positive regulatory signal. This outcome supports future product approvals and export potential. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Granules India rises on USFDA EIR with VAI classification

*Granules India rises on USFDA EIR with VAI classification.* Its subsidiary received an Establishment Inspection Report (EIR) from the USFDA with Voluntary Action Indicated (VAI) status post-inspection. This clears a key regulatory hurdle for exports to the US market. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #USFDA

Granules India offers EPS growth opportunity: Report

*Granules India offers EPS growth opportunity: Report* highlights potential upside based on earnings per share trajectory. The analysis suggests the stock may be undervalued given its growth prospects. Investors eyeing scalable pharma plays could find value here. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #EPS

Granules India Hyderabad facility receives 5 USFDA observations

*Granules India arm gets 5 USFDA observations for Hyderabad facility.* The pharma company's subsidiary received **5 observations** from the US FDA during inspection of its Hyderabad manufacturing facility. These observations typically require corrective action plans but are not critical deficiencies. The company will need to address these compliance issues to maintain its US market certifications. 📊 *STOCKS:* GRANULES | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Compliance